Phase 4Recruiting
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. (CLIgAN)
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
- Sponsor
- Fondazione Schena (Academic or other)
- Enrollment
- 878 planned
- Conditions
- Glomerulonephritis; Immunoglobulin A Nephropathy
- Interventions
- Corticosteroid; Renin-angiotensin sytem blockers; Sodium-glucose cotransporter 2 inhibitor
- Ages
- adults, older adults
- Registry
- NCT04662723
Full record on ClinicalTrials.gov
From the registry
Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy. The high prevalence of ESKD suggests the need to move from a generalized therapy for all patients to personalized therapy. Many RCTs have been conducted stratifying patients based on the laboratory findings (serum creatinine, eGFR and daily proteinuria). In contrast, data from the kidney biopsy has been used only for clinical diagnosis. Therefore, IgAN patients with active or chronic renal lesions have not been equally distributed in experimental and control arms of the randomized clinical trials (RCTs) Our clinical study of IgAN (CLIgAN) is a multicentre, prospective, controlled and open-label randomized clinical trial based on patients' stratification at the time of their kidney biopsy. The investigators will consider, first, the type of renal lesions followed by the serum creatinine values, eGFR and proteinuria. IgAN patients with active renal lesions (n=132)…
Primary outcomes
- -Proteinuria reduction within 6 months in IgAN patients with active renal lesions
- Proteinuria reduction within 6 months in IgAN patients with active renal lesions
- Proteinuria reduction within 6 months in IgAN patients with chronic renal lesions
- Proteinuria reduction within 6 months in IgAN with chronic renal lesions
History
Study completion expected
Primary completion
Last registry update
Started
Registered
Papers citing this trial
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
The Cochrane database of systematic reviews
- Non-immunosuppressive treatment for IgA nephropathy
The Cochrane database of systematic reviews
- Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD
Journal of the American Society of Nephrology : JASN